SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

30 May 2022 Evaluate
Net sales declined -29.82%  to  Rs. 28871.70 million from Rs. 41140.30 millions.A slender decline of -8.07% was recorded to Rs. 8021.60  millions from Rs. 8725.80 millions in the corresponding previous quarter.Operating Profit reported a sharp decline to 9203.40 millions from 12434.50 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 28871.70 41140.30 -29.82 112871.40 158236.80 -28.67 112871.40 158236.80 -28.67
Other Income 4133.70 2674.20 54.58 6709.90 5898.60 13.75 6709.90 5898.60 13.75
PBIDT 9203.40 12434.50 -25.98 21443.90 47096.90 -54.47 21443.90 47096.90 -54.47
Interest 49.10 59.30 -17.20 169.40 286.80 -40.93 169.40 286.80 -40.93
PBDT 8407.20 12375.20 -32.06 20527.40 46810.10 -56.15 20527.40 46810.10 -56.15
Depreciation 1012.20 1240.70 -18.42 4152.60 4880.00 -14.91 4152.60 4880.00 -14.91
PBT 7395.00 11134.50 -33.58 16374.80 41930.10 -60.95 16374.80 41930.10 -60.95
TAX -626.60 2408.70 -126.01 1827.70 10801.00 -83.08 1827.70 10801.00 -83.08
Deferred Tax -880.70 318.90 -376.17 -1969.30 367.60 -635.72 -1969.30 367.60 -635.72
PAT 8021.60 8725.80 -8.07 14547.10 31129.10 -53.27 14547.10 31129.10 -53.27
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 31.88 30.22 5.47 19.00 29.76 -36.17 19.00 29.76 -36.17

Aurobindo Pharma Share Price

1435.90 15.00 (1.06%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×